Terns Pharmaceuticals, Inc. (TERN) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Foster City, CA, 美国. 現任CEO為 Melita Sun Jung.
TERN 擁有 IPO日期為 2021-02-05, 59 名全職員工, 在 NASDAQ Global Select, 市值為 $4.75B.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes TERN-101, a farnesoid X receptor agonist in Phase IIa trials for NASH; TERN-201, a vascular adhesion protein-1 inhibitor in Phase Ib development; TERN-501, a thyroid hormone receptor beta agonist in Phase I trials; and TERN-601, an oral Glucagon-Like Peptide-1 receptor agonist program targeting NASH and metabolic diseases. Founded in 2016 and headquartered in Foster City, California, Terns is advancing both single-agent and combination therapy candidates to address significant unmet medical needs in metabolic disease treatment.
